Product Information
TRI-VYLIBRA 28 TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1264 per EA under NDC 50102023311. Its NADAC has been published 439 times since May 9, 2018.
FDA first approved this application on Jul 6, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Afaxys Pharma, LLCNDC
50102023311
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205441FDA Approved
7/6/2016
TE Code
AB
On Market Since
7/6/2016
Price Statistics
The NADAC for TRI-VYLIBRA 28 TABLET has been published 439 times since May 9, 2018, and over the history we have for it it has declined 46.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1264 per EA |
|---|---|
| All-time high | $0.2397 (Sep 12, 2018) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1259 |
| Median price | $0.1559 |
| Average price | $0.1639 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 439 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Afaxys Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norgestimate and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-VYLIBRA 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-VYLIBRA 28 TABLET, manufactured by Afaxys Pharma, LLC, is $0.1264 per EA (NDC 50102023311), effective Sep 30, 2026.
How has the price of TRI-VYLIBRA 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-VYLIBRA 28 TABLET has declined 46.7%. It has been tracked across 439 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for TRI-VYLIBRA 28 TABLET?
Since May 9, 2018, the NADAC for TRI-VYLIBRA 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2397 (Sep 12, 2018), with a median of $0.1559 per EA.
Are there cheaper alternatives to TRI-VYLIBRA 28 TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1080 per EA — about 15% below TRI-VYLIBRA 28 TABLET.
Who manufactures TRI-VYLIBRA 28 TABLET?
TRI-VYLIBRA 28 TABLET (NDC 50102023311) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.